Modelling α-Synuclein Aggregation and Neurodegeneration with Fibril Seeds in Primary Cultures of Mouse Dopaminergic Neurons

To model α-Synuclein (αS) aggregation and neurodegeneration in Parkinson’s disease (PD), we established cultures of mouse midbrain dopamine (DA) neurons and chronically exposed them to fibrils 91 (F91) generated from recombinant human αS. We found that F91 have an exquisite propensity to seed the aggregation of endogenous αS in DA neurons when compared to other neurons in midbrain cultures. Until two weeks post-exposure, somal aggregation in DA neurons increased with F91 concentrations (0.01–0.75 μM) and the time elapsed since the initiation of seeding, with, however, no evidence of DA cell loss within this time interval. Neither toxin-induced mitochondrial deficits nor genetically induced loss of mitochondrial quality control mechanisms promoted F91-mediated αS aggregation or neurodegeneration under these conditions. Yet, a significant loss of DA neurons (~30%) was detectable three weeks after exposure to F91 (0.5 μM), i.e., at a time point where somal aggregation reached a plateau. This loss was preceded by early deficits in DA uptake. Unlike αS aggregation, the loss of DA neurons was prevented by treatment with GDNF, suggesting that αS aggregation in DA neurons may induce a form of cell death mimicking a state of trophic factor deprivation. Overall, our model system may be useful for exploring PD-related pathomechanisms and for testing molecules of therapeutic interest for this disorder.

[1]  L. Stefanis,et al.  Endogenous Levels of Alpha-Synuclein Modulate Seeding and Aggregation in Cultured Cells , 2021, Molecular Neurobiology.

[2]  J. Trojanowski,et al.  Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro , 2021, Acta neuropathologica communications.

[3]  D. Surmeier,et al.  Disruption of mitochondrial complex I induces progressive parkinsonism , 2021, Nature.

[4]  P. Michel,et al.  The Chemically-Modified Tetracycline COL-3 and Its Parent Compound Doxycycline Prevent Microglial Inflammatory Responses by Reducing Glucose-Mediated Oxidative Stress , 2021, Cells.

[5]  R. Fischer,et al.  Phenotypic manifestation of α-synuclein strains derived from Parkinson’s disease and multiple system atrophy in human dopaminergic neurons , 2021, Nature Communications.

[6]  C. Dobson,et al.  The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells , 2021, Nature Communications.

[7]  Gabriel Dias de Abreu,et al.  Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson’s Disease , 2021, Frontiers in Pharmacology.

[8]  D. Surmeier,et al.  Determinants of seeding and spreading of α-synuclein pathology in the brain , 2020, Science Advances.

[9]  P. Gracia,et al.  Multiplicity of α-Synuclein Aggregated Species and Their Possible Roles in Disease , 2020, International journal of molecular sciences.

[10]  C. Follmer,et al.  In Vitro Protective Action of Monomeric and Fibrillar α-Synuclein on Neuronal Cells Exposed to the Dopaminergic Toxins Salsolinol and DOPAL. , 2020, ACS chemical neuroscience.

[11]  R. Moratalla,et al.  Modeling Parkinson’s Disease With the Alpha-Synuclein Protein , 2020, Frontiers in Pharmacology.

[12]  C. Sandi,et al.  Pronounced α-Synuclein Pathology in a Seeding-Based Mouse Model Is Not Sufficient to Induce Mitochondrial Respiration Deficits in the Striatum and Amygdala , 2020, bioRxiv.

[13]  J. Peyrin,et al.  The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding , 2020, Scientific Reports.

[14]  G. Knott,et al.  The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration , 2020, Proceedings of the National Academy of Sciences.

[15]  A. Triller,et al.  Differential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs , 2020, Biophysical journal.

[16]  P. McLean,et al.  Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway , 2020, Molecular Neurodegeneration.

[17]  A. Raj,et al.  Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation , 2019, Neurobiology of Disease.

[18]  Joseph R. Patterson,et al.  Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils , 2019, Neurobiology of Disease.

[19]  K. Luk,et al.  GDNF/RET signaling pathway activation eliminates Lewy Body pathology in midbrain dopamine neurons , 2019, bioRxiv.

[20]  J. Kordower,et al.  Spreading of alpha‐synuclein – relevant or epiphenomenon? , 2019, Journal of neurochemistry.

[21]  P. Alam,et al.  α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities , 2019, Journal of neurochemistry.

[22]  D. Sulzer,et al.  The physiological role of α‐synuclein and its relationship to Parkinson’s Disease , 2019, Journal of neurochemistry.

[23]  W. V. van IJcken,et al.  Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes , 2019, Nature Neuroscience.

[24]  A. Perrier,et al.  Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network , 2019, Stem cell reports.

[25]  A. West,et al.  Sensitivity and specificity of phospho‐Ser129 α‐synuclein monoclonal antibodies , 2018, The Journal of comparative neurology.

[26]  L. Trudeau,et al.  On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease , 2018, Front. Neurol..

[27]  Michael J. Devine,et al.  α-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease , 2018, Nature Communications.

[28]  A. Brice,et al.  Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20‐dependent negative feedback loop , 2018, Glia.

[29]  S. Xie,et al.  Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity , 2018, Acta Neuropathologica.

[30]  M. Feany,et al.  α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton , 2018, Neuron.

[31]  M. Goedert,et al.  Neurodegeneration and the ordered assembly of α-synuclein , 2017, Cell and Tissue Research.

[32]  Xiaomin Su,et al.  Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  J. Kordower,et al.  Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins , 2017, Acta Neuropathologica.

[34]  J. Kordower,et al.  Aging and Parkinson’s Disease: Different Sides of the Same Coin? , 2017, Movement disorders : official journal of the Movement Disorder Society.

[35]  E. Hirsch,et al.  The noble gas xenon provides protection and trophic stimulation to midbrain dopamine neurons , 2017, Journal of neurochemistry.

[36]  S. Przedborski The two-century journey of Parkinson disease research , 2017, Nature Reviews Neuroscience.

[37]  V. Torre,et al.  An improved method for growing neurons: Comparison with standard protocols , 2017, Journal of Neuroscience Methods.

[38]  K. Thorn,et al.  α-Synuclein Promotes Dilation of the Exocytotic Fusion Pore , 2017, Nature Neuroscience.

[39]  A. Makky,et al.  Nanomechanical properties of distinct fibrillar polymorphs of the protein α-synuclein , 2016, Scientific Reports.

[40]  P. Michel,et al.  A simplified approach for efficient isolation of functional microglial cells: Application for modeling neuroinflammatory responses in vitro , 2016, Glia.

[41]  E. Hirsch,et al.  Understanding Dopaminergic Cell Death Pathways in Parkinson Disease , 2016, Neuron.

[42]  R. Melki,et al.  Structural and functional properties of prefibrillar α-synuclein oligomers , 2016, Scientific Reports.

[43]  D. Dickson,et al.  Proaggregant nuclear factor(s) trigger rapid formation of α-synuclein aggregates in apoptotic neurons , 2016, Acta Neuropathologica.

[44]  Philipp Selenko,et al.  Structural disorder of monomeric α-synuclein persists in mammalian cells , 2016, Nature.

[45]  B. Liss,et al.  GDNF–Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease , 2015, FEBS letters.

[46]  M. Emborg,et al.  α-Synuclein and nonhuman primate models of Parkinson's disease , 2015, Journal of Neuroscience Methods.

[47]  H. Qing,et al.  The phosphorylation of α‐synuclein: development and implication for the mechanism and therapy of the Parkinson's disease , 2015, Journal of neurochemistry.

[48]  Stephanie M. Williams,et al.  Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson’s Disease Brains Are Differentially Generated in Mammalian Cell Models , 2015, Biomolecules.

[49]  D. Klenerman,et al.  Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons , 2015, Cell Death and Disease.

[50]  V. Baekelandt,et al.  Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration , 2015, Molecular Neurodegeneration.

[51]  K. Gamble,et al.  Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes , 2014, Molecular biology of the cell.

[52]  P. Greengard,et al.  Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update , 2014, Front. Neuroanat..

[53]  A. Schapira,et al.  Targeting mitochondria for neuroprotection in Parkinson disease. , 2014, JAMA neurology.

[54]  E. Hirsch,et al.  The Iron-Binding Protein Lactoferrin Protects Vulnerable Dopamine Neurons from Degeneration by Preserving Mitochondrial Calcium Homeostasis , 2013, Molecular Pharmacology.

[55]  Richard Wade-Martins,et al.  Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model , 2013, Proceedings of the National Academy of Sciences.

[56]  P. Baas,et al.  Mitotic Motors Coregulate Microtubule Patterns in Axons and Dendrites , 2012, The Journal of Neuroscience.

[57]  K. Kirkegaard,et al.  Neuron‐to‐neuron transmission of α‐synuclein fibrils through axonal transport , 2012, Annals of neurology.

[58]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[59]  R. R. Reijo Pera,et al.  Modeling Parkinson’s Disease Using Induced Pluripotent Stem Cells , 2012, Current Neurology and Neuroscience Reports.

[60]  Tanja Waldmann,et al.  Rapid, complete and large‐scale generation of post‐mitotic neurons from the human LUHMES cell line , 2011, Journal of neurochemistry.

[61]  A. Brice,et al.  What genetics tells us about the causes and mechanisms of Parkinson's disease. , 2011, Physiological reviews.

[62]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[63]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[64]  Uwe Walter,et al.  No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism , 2009, Movement disorders : official journal of the Movement Disorder Society.

[65]  Kostas Vekrellis,et al.  Inducible over‐expression of wild type α‐synuclein in human neuronal cells leads to caspase‐dependent non‐apoptotic death , 2009, Journal of neurochemistry.

[66]  E. Hirsch,et al.  Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels , 2008, Molecular Pharmacology.

[67]  Hitoshi Takahashi,et al.  The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates , 2007, Neuropathology : official journal of the Japanese Society of Neuropathology.

[68]  J. Mallet,et al.  PA700, the regulatory complex of the 26S proteasome, interferes with α‐synuclein assembly , 2005 .

[69]  A. R. Vancha,et al.  Use of polyethyleneimine polymer in cell culture as attachment factor and lipofection enhancer , 2004, BMC biotechnology.

[70]  D. Perl,et al.  Lewy-body formation is an aggresome-related process: a hypothesis , 2004, The Lancet Neurology.

[71]  J. Joseph,et al.  α-Synuclein Up-regulation and Aggregation during MPP+-induced Apoptosis in Neuroblastoma Cells , 2004, Journal of Biological Chemistry.

[72]  A. Lees,et al.  Alteration in α‐synuclein mRNA expression in Parkinson's disease , 2004 .

[73]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[74]  D. Sulzer,et al.  Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis , 2002, The Journal of Neuroscience.

[75]  S. Shin,et al.  Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors* , 2002, The Journal of Biological Chemistry.

[76]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[77]  R. Burke,et al.  α‐Synuclein expression in substantia nigra and cortex in Parkinson's disease , 1999 .

[78]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[79]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[80]  Y. Agid,et al.  Rescue of Mesencephalic Dopamine Neurons by Anticancer Drug Cytosine Arabinoside , 1997, Journal of neurochemistry.

[81]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[82]  F. Hefti,et al.  Toxicity of 1‐Methyl‐4‐Phenylpyridinium for Rat Dopaminergic Neurons in Culture: Selectivity and Irreversibility , 1990, Journal of neurochemistry.

[83]  P. Danias,et al.  Mesencephalic Dopamine Neurons Become Less Sensitive to 1 ‐Methyl‐4‐Phenyl‐l,2,3,6‐Tetrahydropyridine Toxicity During Development In Vitro , 1989, Journal of neurochemistry.

[84]  G. Banker Trophic interactions between astroglial cells and hippocampal neurons in culture. , 1980, Science.

[85]  Y Agid,et al.  Relationship of aging to Parkinson's disease. , 1987, Advances in neurology.